Autolus Therapeutics plc Lease, Cost
Autolus Therapeutics plc (AUTL) reported Lease, Cost of $3.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-11
- Autolus Therapeutics plc lease, cost for the quarter ending 2026-06-30 was $3.26M, a 30.91% increase year-over-year.
- Autolus Therapeutics plc lease, cost for the quarter ending 2026-03-31 was $3.03M, a 12.93% increase year-over-year.
- Autolus Therapeutics plc lease, cost for the quarter ending 2025-12-31 was $2.98M, a 5.51% increase year-over-year.
- Autolus Therapeutics plc lease, cost for the quarter ending 2025-09-30 was $2.94M, a 23.53% increase year-over-year.
- Autolus Therapeutics plc lease, cost for fiscal 2025 was $11.10M, a 4.45% increase from fiscal 2024.
- Autolus Therapeutics plc lease, cost for fiscal 2024 was $10.63M, a 14.76% increase from fiscal 2023.
- Autolus Therapeutics plc lease, cost for fiscal 2023 was $9.26M, a 57.36% increase from fiscal 2022.
- Autolus Therapeutics plc lease, cost for fiscal 2022 was $5.89M, a 21.24% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.26M 10-Q · filed 2026-08-11 | $6.29M 10-Q · filed 2026-08-11 | $9.28M derived: sum of 3 quarters · filed 2026-08-11 | $12.22M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $3.03M 10-Q · filed 2026-05-14 | $6.01M derived: sum of 2 quarters · filed 2026-05-14 | $8.96M derived: sum of 3 quarters · filed 2026-05-14 | $11.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $5.93M derived: sum of 2 quarters · filed 2026-03-27 | $8.42M derived: sum of 3 quarters · filed 2026-08-11 | $11.10M 10-K · filed 2026-03-27 |
| 2025-09-30 | $2.94M 10-Q · filed 2025-11-12 | $5.44M derived: sum of 2 quarters · filed 2026-08-11 | $8.12M 10-Q · filed 2025-11-12 | $10.95M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.49M 10-Q · filed 2026-08-11 | $5.17M 10-Q · filed 2026-08-11 | $8.00M derived: sum of 3 quarters · filed 2026-08-11 | $10.39M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $2.68M 10-Q · filed 2026-05-14 | $5.51M derived: sum of 2 quarters · filed 2026-05-14 | $7.90M derived: sum of 3 quarters · filed 2026-05-14 | $10.57M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $5.21M derived: sum of 2 quarters · filed 2026-03-27 | $7.89M derived: sum of 3 quarters · filed 2026-03-27 | $10.63M 10-K · filed 2026-03-27 |
| 2024-09-30 | $2.38M 10-Q · filed 2025-11-12 | $5.06M derived: sum of 2 quarters · filed 2025-11-12 | $7.80M 10-Q · filed 2025-11-12 | $10.72M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.67M 10-Q · filed 2025-08-12 | $5.42M 10-Q · filed 2025-08-12 | $8.34M derived: sum of 3 quarters · filed 2025-08-12 | $11.20M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.74M 10-Q · filed 2025-05-08 | $5.66M derived: sum of 2 quarters · filed 2025-05-08 | $8.53M derived: sum of 3 quarters · filed 2025-05-08 | $10.89M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $5.78M derived: sum of 2 quarters · filed 2025-03-20 | $8.14M derived: sum of 3 quarters · filed 2025-03-20 | $9.26M 10-K · filed 2025-03-20 |
| 2023-09-30 | $2.86M 10-Q · filed 2024-11-12 | $5.22M derived: sum of 2 quarters · filed 2024-11-12 | $6.34M 10-Q · filed 2024-11-12 | $7.74M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $2.36M 10-Q · filed 2024-08-08 | $3.50M 10-Q · filed 2024-08-08 | $4.88M derived: sum of 3 quarters · filed 2024-08-08 | $6.37M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.12M 10-Q · filed 2024-05-17 | $2.52M derived: sum of 2 quarters · filed 2024-05-17 | $4.00M derived: sum of 3 quarters · filed 2024-05-17 | |
| 2022-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.88M derived: sum of 2 quarters · filed 2024-03-21 | $5.89M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $1.49M 10-Q · filed 2023-11-09 | $4.49M 10-Q · filed 2023-11-09 | ||
| 2021-12-31 | $7.47M 10-K · filed 2024-03-21 | |||
| 2020-12-31 | $8.41M 20-F · filed 2022-03-10 | |||
| 2019-12-31 | $1.60M derived: 20-F 12 month − 6-K 9 month · filed 2021-03-04 | $3.13M derived: sum of 2 quarters · filed 2021-03-04 | $4.72M derived: sum of 3 quarters · filed 2021-03-04 | $6.14M 20-F · filed 2021-03-04 |
| 2019-09-30 | $1.53M 6-K · filed 2019-11-07 | $3.12M derived: sum of 2 quarters · filed 2019-11-07 | $4.54M 6-K · filed 2019-11-07 | |
| 2019-06-30 | $1.59M 6-K · filed 2019-08-08 | $3.06M 6-K · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |